Imposing certain health insurance coverage requirements for screening and diagnostic examinations for breast cancer.
Impact
If enacted, the bill would require insurers to provide comprehensive coverage for breast cancer screening and related diagnostic examinations. This requirement enhances the legal obligations of health insurers within the state, ensuring that women have equitable access to vital health services. By specifying these coverage requirements, the bill aims to reduce the financial barriers that have historically prevented many from seeking necessary evaluations and interventions related to breast cancer.
Summary
SB161 mandates specific health insurance coverage requirements for screening and diagnostic examinations for breast cancer. This legislative move aims to improve access to critical preventive services for women, making sure that insurance providers cover these essential health needs without imposing excessive costs on patients. The bill highlights the importance of timely diagnosis and treatment options for breast cancer, which can significantly impact patient outcomes and survival rates.
Contention
Discussions surrounding SB161 have raised concerns from various stakeholders. Supporters argue that the bill is crucial for women's health rights, ensuring that all women, regardless of their financial means, can receive necessary screenings and diagnostics. However, some opponents have expressed worries about the fiscal implications for insurance companies and the possibility of increased insurance premiums as a result of mandated coverage. The balance between providing comprehensive health benefits and sustaining affordable insurance options remains a point of contention among legislators and advocacy groups.
Requiring that certain health insurance plans impose no-cost sharing requirement on insured individuals for diagnostic breast examinations for breast cancer.
Requiring that certain health insurance plans impose a no-cost sharing requirement for a diagnostic or supplemental breast cancer examination for breast cancer imposed on an insured.